New government drug repurposing programs: Opportunities and uncertainties

Johnathon Liddicoat*, Ashleigh Hamidzadeh, Kathleen Liddell, Marco Schito, David Simon, Mateo Aboy, Timo Minssen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, partially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europe have created seven drug development programs that aim to overcome these challenges using a variety of different strategies.

Original languageEnglish
Article numberadl0998
JournalScience translational medicine
Volume16
Issue number753
DOIs
Publication statusPublished - 2024

Fingerprint

Dive into the research topics of 'New government drug repurposing programs: Opportunities and uncertainties'. Together they form a unique fingerprint.

Cite this